Drug intelligence / Profile preview

KHN939

Development stage: Phase 3
Lead developer: Pro-heal Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KHN939 (also known as PHP1003) is a recombinant humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). Developed by Suzhou Pulexon Pharmaceutical Technology, it is primarily being investigated for the treatment of moderate-to-severe active thyroid eye disease (TED). By binding to IGF-1R, KHN939 inhibits the signaling pathway that drives the inflammation and tissue expansion behind the eyes in TED patients, similar to the mechanism of teprotumumab. It is currently in Phase 3 clinical trials in China.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on KHN939.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KHN939.

Explore the full profile